Get the Stockscreener App
1.22
36.11%
0.32
Geovax Labs Inc stock is traded at $1.22, with a volume of 8.84M.
It is up +36.11% in the last 24 hours and up +24.39% over the past month.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
See More
Previous Close:
$0.90
Open:
$1.05
24h Volume:
8.84M
Relative Volume:
15.42
Market Cap:
$18.54M
Revenue:
$356.60K
Net Income/Loss:
$-24.32M
P/E Ratio:
-0.132
EPS:
-9.24
Net Cash Flow:
$-27.24M
1W Performance:
+7.46%
1M Performance:
+24.39%
6M Performance:
-45.31%
1Y Performance:
-35.53%
1-Day Range:
$1.03
$1.23
1-Week Range:
$0.89
$1.39
52-Week Range:
$0.73
$11.18
Geovax Labs Inc Stock (GOVX) Company Profile
Name
Geovax Labs Inc
Sector
Industry
Phone
678-384-7220
Address
1900 LAKE PARK DRIVE, SMYRNA
Compare GOVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
1.2204 | 18.54M | 356.60K | -24.32M | -27.24M | -9.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.72 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
518.23 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.74 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
544.13 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.37 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Reiterated | Alliance Global Partners | Buy |
| Apr-15-25 | Reiterated | D. Boral Capital | Buy |
| Nov-11-24 | Initiated | Alliance Global Partners | Buy |
| Jul-16-24 | Initiated | ROTH MKM | Buy |
| Nov-19-20 | Initiated | Maxim Group | Buy |
Geovax Labs Inc Stock (GOVX) Latest News
Geovax Labs Inc Inc. (GOVX) Price Performance: Is It Undervalued or Overvalued? - investchronicle.com
GeoVax Labs (GOVX) Gains Positive EMA Feedback, Potential Speedier Approval | GOVX Stock News - GuruFocus
GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting - Yahoo Finance
GeoVax Advances Toward European Approval for Mpox and Smallpox Vaccine with EMA's Support - citybuzz -
GeoVax Labs’ (GOVX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
GeoVax Labs (GOVX) Issues New Stock Units with Warrants | GOVX Stock News - GuruFocus
GeoVax Labs (GOVX) Gains EMA Approval for Phase 3 Vaccine Trial | GOVX Stock News - GuruFocus
GOVX: Geovax Labs Receives Buy Rating from Analyst | GOVX Stock News - GuruFocus
GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA - Yahoo Finance
GeoVax to Showcase Innovative Vaccines and Therapies at BIO International Convention 2025 - citybuzz -
GeoVax to Participate in BIO International Convention 2025 - Yahoo Finance
Geovax highlights progress on mpox vaccine and COVID-19 trial advancements - MSN
GeoVax Advances GEO-MVA Vaccine Development Amid WHO's Mpox Emergency Declaration - citybuzz -
GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency - Yahoo Finance
Robinhood Markets, Inc. Reports May 2025 Operating Data - The Globe and Mail
GeoVax to Showcase Positive Immune Response Data for GEO-CM04S1 in CLL Patients at EHA 2025 Congress - citybuzz -
GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients - Yahoo Finance
42,275 Shares in GeoVax Labs, Inc. (NASDAQ:GOVX) Acquired by Citadel Advisors LLC - Defense World
GeoVax’s Multi-Antigen COVID-19 Vaccine Candidates Show Promise Against Variants - citybuzz -
GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia - Yahoo Finance
Northern Trust Corp Invests $29,000 in GeoVax Labs, Inc. (NASDAQ:GOVX) - Defense World
GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Analysts - Defense World
GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing - Yahoo Finance
GeoVax Labs (NASDAQ:GOVX) Shares Up 6.9% – Should You Buy? - Defense World
GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance - Yahoo Finance
GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation - Yahoo Finance
GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations - Yahoo Finance
GeoVax Labs (GOVX) Projected to Post Earnings on Tuesday - Defense World
GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025 - Yahoo Finance
GeoVax Strengthens Patent Portfolio for Innovative Cancer Therapy Approach - citybuzz -
GeoVax Expands Gedeptin(R) Patent Portfolio - Yahoo Finance
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production - Yahoo Finance
MarketsMedicine Hat News - FinancialContent
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - ADVFN
D. Boral Capital Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $9.00 - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Form 8-KCurrent report - ADVFN
Geode Capital Management LLC Has $223,000 Holdings in GeoVax Labs, Inc. (NASDAQ:GOVX) - Defense World
Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and Baxter International (BAX) - The Globe and Mail
GeoVax Labs Earnings Call: Mixed Sentiment and Future Prospects - TipRanks
Geovax Labs (GOVX) Faces Price Target Reduction by Analyst | GOV - GuruFocus
Geovax Labs (GOVX) Faces Price Target Reduction by Analyst | GOVX Stock News - GuruFocus
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
GeoVax Labs Reports Q1 2025 Progress Amid Challenges - TipRanks
Earnings call transcript: GeoVax Q1 2025 reveals revenue from BARDA contract - Investing.com Australia
GeoVax Labs Q1 2025 Earnings Call Transcript - MarketBeat
GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting - Yahoo Finance
Geovax Labs is a buy, Roth says - Cantech Letter
GOVX’s 2023 Market Dance: Down -59.51% – Time to Invest? - investchronicle.com
Geovax Labs Inc Stock (GOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Geovax Labs Inc Stock (GOVX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sharkey John W. | VP, Business Development |
Apr 10 '25 |
Buy |
0.99 |
6,000 |
5,940 |
6,191 |
| DODD DAVID A | President, CEO |
Apr 01 '25 |
Buy |
1.08 |
10,000 |
10,800 |
36,661 |
| Reynolds Mark | CFO |
Mar 31 '25 |
Buy |
1.08 |
6,800 |
7,343 |
14,013 |
| DODD DAVID A | President, CEO |
Aug 09 '24 |
Buy |
1.95 |
8,000 |
15,600 |
26,661 |
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):